1921
Volume 103, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Transcutaneous vaccination can induce both mucosal and systemic immune responses. However, there are few data on anti-polysaccharide responses following transcutaneous vaccination of polysaccharides, despite the role that anti-polysaccharide responses play in protecting against intestinal mucosal and respiratory pathogens. Whether transcutaneous vaccination with a conjugate polysaccharide vaccine would be able to induce memory responses is also unknown. To address this, we transcutaneously vaccinated mice with virulence antigen (Vi) polysaccharide of serovar Typhi (the cause of typhoid fever), either in unconjugated or conjugated form (the latter as a Vi-DT conjugate). We also assessed the ability of the immunoadjuvant cholera toxin to impact responses following vaccination. We found that presenting Vi in a conjugate versus nonconjugate form transcutaneously resulted in comparable serum IgG responses but higher serum and lamina propria lymphocyte IgA anti-Vi responses, as well as increased IgG memory responses. The addition of immunoadjuvant did not further increase these responses; however, it boosted fecal IgA and serum IgG anti-Vi responses. Our results suggest that transcutaneous vaccination of a conjugate vaccine can induce systemic as well as enhanced mucosal and memory B-cell anti-polysaccharide responses.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0798
2020-07-27
2020-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/3/tpmd190798.html?itemId=/content/journals/10.4269/ajtmh.19-0798&mimeType=html&fmt=ahah

References

  1. Chen D, Colditz IG, Glenn GM, Tsonis CG, 2002. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep. Vet Immunol Immunopathol 86: 177182.
    [Google Scholar]
  2. Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA, 2007. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 75: 21632170.
    [Google Scholar]
  3. McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM, 2007. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25: 36843691.
    [Google Scholar]
  4. Rollenhagen JE, Kalsy A, Saksena R, Sheikh A, Alam MM, Qadri F, Calderwood SB, Kovac P, Ryan ET, 2009. Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice. Vaccine 27: 49174922.
    [Google Scholar]
  5. Medise BE et al., 2019. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. PLoS One 14: e0211784.
    [Google Scholar]
  6. Radhakrishnan A, Als D, Mintz ED, Crump JA, Stanaway J, Breiman RF, Bhutta ZA, 2018. Introductory article on global burden and epidemiology of typhoid fever. Am J Trop Med Hyg 99: 49.
    [Google Scholar]
  7. Lhocine N, Arena ET, Bomme P, Ubelmann F, Prevost MC, Robine S, Sansonetti PJ, 2015. Apical invasion of intestinal epithelial cells by Salmonella typhimurium requires villin to remodel the brush border actin cytoskeleton. Cell Host Microbe 17: 164177.
    [Google Scholar]
  8. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens JD, Bhan MK, 1999. Typhoid fever in children aged less than 5 years. Lancet 354: 734737.
    [Google Scholar]
  9. Milligan R, Paul M, Richardson M, Neuberger A, 2018. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 5: CD001261.
    [Google Scholar]
  10. Sur D et al., 2009. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 361: 335344.
    [Google Scholar]
  11. Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, Clemens JD, 2010. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 17: 7379.
    [Google Scholar]
  12. Capeding MR et al., 2018. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in healthy Filipino adults and children. Vaccine 36: 37943801.
    [Google Scholar]
  13. Rollenhagen JE, Kalsy A, Cerda F, John M, Harris JB, Larocque RC, Qadri F, Calderwood SB, Taylor RK, Ryan ET, 2006. Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice. Infect Immun 74: 58345839.
    [Google Scholar]
  14. Sheikh A et al., 2009. Salmonella enterica serovar Typhi-specific immunoglobulin A antibody responses in plasma and antibody in lymphocyte supernatant specimens in Bangladeshi patients with suspected typhoid fever. Clin Vaccine Immunol 16: 15871594.
    [Google Scholar]
  15. Tarique AA et al., 2012. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin Vaccine Immunol 19: 594602.
    [Google Scholar]
  16. Sayeed MA et al., 2015. A cholera conjugate vaccine containing O-specific polysaccharide (OSP) of V. cholerae O1 inaba and recombinant fragment of tetanus toxin heavy chain (OSP:rTTHc) induces serum, memory and lamina proprial responses against OSP and is protective in mice. PLoS Negl Trop Dis 9: e0003881.
    [Google Scholar]
  17. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB, 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med 160: 521540.
    [Google Scholar]
  18. Slifka MK, Ahmed R, 1996. Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J Immunol Methods 199: 3746.
    [Google Scholar]
  19. Mawas F, Peyre M, Beignon AS, Frost L, Del Giudice G, Rappuoli R, Muller S, Sesardic D, Partidos CD, 2004. Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. J Infect Dis 190: 11771182.
    [Google Scholar]
  20. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA, 2004. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113: 9981007.
    [Google Scholar]
  21. Enioutina EY, Visic D, Daynes RA, 2000. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18: 27532767.
    [Google Scholar]
  22. Norton E, Clements J, 2013. cAMP-based adjuvants (LT, mLT, dmLT) promote Th17 and germinal center responses through dendritic cells, while direct CD4 T-cell contact induces a T-suppressor phenotype (P4512). J Immunol 190 (Suppl 1): 178.10.
    [Google Scholar]
  23. Clements JD, Norton EB, 2018. The mucosal vaccine adjuvant LT(R192G/L211A) or dmLT. mSphere 3: e00215-18.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0798
Loading
/content/journals/10.4269/ajtmh.19-0798
Loading

Data & Media loading...

  • Received : 27 Oct 2019
  • Accepted : 19 Jun 2020
  • Published online : 27 Jul 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error